TY  - JOUR
AU  - Antić, Darko
AU  - Mihaljević, Biljana
AU  - Cokić, Vladan
AU  - Fekete, Marija Dencic
AU  - Karan-Đurašević, Teodora
AU  - Pavlović, Sonja
AU  - Milić, Nataša
AU  - Elezović, Ivo
PY  - 2011
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/518
AB  - We investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of beta(2)-microglobulin (beta M-2) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of beta M-2, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p  lt  0.0001).
PB  - Taylor & Francis Ltd, Abingdon
T2  - Leukemia & Lymphoma
T1  - Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling
EP  - 1397
IS  - 7
SP  - 1394
VL  - 52
DO  - 10.3109/10428194.2011.578311
ER  - 

@article{
author = "Antić, Darko and Mihaljević, Biljana and Cokić, Vladan and Fekete, Marija Dencic and Karan-Đurašević, Teodora and Pavlović, Sonja and Milić, Nataša and Elezović, Ivo",
year = "2011",
abstract = "We investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of beta(2)-microglobulin (beta M-2) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of beta M-2, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p  lt  0.0001).",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Leukemia & Lymphoma",
title = "Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling",
pages = "1397-1394",
number = "7",
volume = "52",
doi = "10.3109/10428194.2011.578311"
}

Antić, D., Mihaljević, B., Cokić, V., Fekete, M. D., Karan-Đurašević, T., Pavlović, S., Milić, N.,& Elezović, I.. (2011). Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling. in Leukemia & Lymphoma
Taylor & Francis Ltd, Abingdon., 52(7), 1394-1397.
https://doi.org/10.3109/10428194.2011.578311

Antić D, Mihaljević B, Cokić V, Fekete MD, Karan-Đurašević T, Pavlović S, Milić N, Elezović I. Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling. in Leukemia & Lymphoma. 2011;52(7):1394-1397.
doi:10.3109/10428194.2011.578311 .

Antić, Darko, Mihaljević, Biljana, Cokić, Vladan, Fekete, Marija Dencic, Karan-Đurašević, Teodora, Pavlović, Sonja, Milić, Nataša, Elezović, Ivo, "Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling" in Leukemia & Lymphoma, 52, no. 7 (2011):1394-1397,
https://doi.org/10.3109/10428194.2011.578311 . .